CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 353,980 enrolled
Drug / intervention
Rivaroxaban +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05256797
NCT05256797N/ACompleted
CompareCT.gov

Prediction of the COBRRA AF Anticoagulant Trial in Healthcare Claims Data

Brigham and Women's Hospital·observational·Posted Feb 25, 2022·Updated Mar 4, 2025

In Brief

An observational study evaluating Rivaroxaban and Apixaban for Atrial Fibrillation. Completed, enrolled 353,980 participants across 1 site.

Detailed Summary

Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedFeb 25, 2022
Enrollment StartMay 3, 2021
Primary CompletionJun 15, 2022
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 4.4 years ago

Interventions

Rivaroxabandrug

Any rivaroxaban dispensing claim is used as the reference group

Apixabandrug

Any apixaban dispensing claim is used as the exposure group